Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers

Abstract Alzheimer's disease (AD) is the most common cause of dementia. Neuropathological changes in AD patients occur up to 10–20 years before emergence clinical symptoms. Specific diagnosis and appropriate intervention strategies are crucial during phase mild cognitive impairment (MCI) AD. The detection biomarkers has emerged as a promising tool for tracking efficacy potential therapies, making an early diagnosis, prejudging treatment prognosis. Specifically, multiple neuroimaging modalities, including magnetic resonance imaging (MRI), positron emission tomography, optical imaging, single photon emission-computed have provided few application. MRI modalities described this review include structural MRI, functional diffusion tensor spectroscopy, arterial spin labelling. These techniques allow presymptomatic diagnostic brains cognitively normal elderly people might also be used monitor progression after onset This highlights biomarkers, merits demerits different their value MCI patients. Further studies necessary explore more overcome limitations inclusion criteria